- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05196399
Bioequivalence Study of Different Aprocitentan Tablet Formulations
November 22, 2022 updated by: Idorsia Pharmaceuticals Ltd.
A Single-center, Open-label, Randomized, Two-way Crossover Phase 1 Study to Compare the Single-dose Pharmacokinetics of Different Tablet Formulations of Aprocitentan in Healthy Subjects
The main purpose is to study the pharmacokinetics of aprocitentan (ACT-132577) using 2 different tablet formulations.
The clinical pharmacology data will be used to determine bioequivalence of 2 different tablet formulations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Pilsen, Czechia, 323 00
- CEPHA s.r.o.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent in a language understandable to the participant prior to any study-mandated procedure.
- Healthy male or female participant aged between 18 and 55 years (inclusive) at Screening.
- Body Mass Index of 18.0 to 30.0 kg/m2 (inclusive) at Screening.
- Systolic blood pressure (SBP) 100-140 mmHg, Diastolic blood pressure (DBP) 60-90 mmHg, and pulse rate 60-100 bpm (inclusive), measured on the dominant arm, after 5 min in the supine position at Screening and on Day 1 pre-dose of the first period.
- Woman of Childbearing Potential who has a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1 of the first period. She must agree to consistently and correctly use (from Screening, during the entire study, and for at least 30 days after the last study treatment administration) a highly effective method of contraception with a failure rate of less than 1% per year.
- Woman of non-childbearing potential, i.e., postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause; in addition, an FSH test must be performed at Screening to further support postmenopausal status), with previous bilateral salpingectomy, bilateral salpingo oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, uterine agenesis.
Exclusion Criteria:
- Pregnant or lactating woman.
- Previous administration of aprocitentan.
- Known hypersensitivity to endothelin receptor antagonists or to excipients used in any of the formulations.
- History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatments (appendectomy and herniotomy allowed, cholecystectomy not allowed).
- Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation of the study results.
- Clinically relevant findings on the physical examination at Screening and on Day -1 of the first period.
- Clinically relevant findings in clinical laboratory tests (hematology and clinical chemistry) at Screening and on Day -1 of the first period.
- Previous treatment with any prescribed medications (including vaccines) or over-the-counter medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 3 weeks or 5 terminal elimination half-lives (t½; whichever is longer) prior to first study treatment administration.
- Legal incapacity or limited legal capacity at Screening.
- Positive COVID-19 test, if performed (subject to current epidemiological regulations in the Czech Republic) during the screening period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aprocitentan (reference product)
25 mg film-coated tablet
|
A single oral dose of 25 mg.
Other Names:
|
Experimental: Aprocitentan (test product)
25 mg film-coated tablet
|
A single oral dose of 25 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum plasma concentration (Cmax) of aprocitentan
Time Frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
|
Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
|
The area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of aprocitentan
Time Frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
|
Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
|
Area under the plasma concentration-time curve from zero to infinity (AUC0-inf) of aprocitentan
Time Frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
|
Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 10.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment-emergent adverse events
Time Frame: From study treatment administration on Day 1 up to last assessment at End of Period (Day 10).
|
From study treatment administration on Day 1 up to last assessment at End of Period (Day 10).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 2, 2022
Primary Completion (Actual)
March 27, 2022
Study Completion (Actual)
April 7, 2022
Study Registration Dates
First Submitted
January 5, 2022
First Submitted That Met QC Criteria
January 5, 2022
First Posted (Actual)
January 19, 2022
Study Record Updates
Last Update Posted (Actual)
November 23, 2022
Last Update Submitted That Met QC Criteria
November 22, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- ID-080-110
- 2021-005090-11 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Aprocitentan (Formulation A)
-
Idorsia Pharmaceuticals Ltd.Janssen Biotech, Inc.CompletedResistant HypertensionSpain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy Subjects | Severe Renal ImpairmentCzechia
-
ViiV HealthcareGlaxoSmithKlineNot yet recruiting
-
GlaxoSmithKlineCompletedMultiple SclerosisPoland, Germany, Czechia
-
Medicines for Malaria VentureRichmond Pharmacology LimitedCompleted
-
Lyndra Inc.CompletedHealthy | Gastric RetentionAustralia
-
Idorsia Pharmaceuticals Ltd.Completed
-
ViiV HealthcareRecruiting
-
Vertex Pharmaceuticals IncorporatedCompletedChronic Hepatitis CUnited States
-
Idorsia Pharmaceuticals Ltd.Janssen Biotech, Inc.Completed